-
1 Comment
Beijing Konruns Pharmaceutical Co.,Ltd is currently in a long term downtrend where the price is trading 3.3% below its 200 day moving average.
From a valuation standpoint, the stock is 29.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.8.
Beijing Konruns Pharmaceutical Co.,Ltd's total revenue sank by 15.1% to $259M since the same quarter in the previous year.
Its net income has dropped by 33.3% to $42M since the same quarter in the previous year.
Finally, its free cash flow fell by 148.0% to $-24M since the same quarter in the previous year.
Based on the above factors, Beijing Konruns Pharmaceutical Co.,Ltd gets an overall score of 1/5.
| CurrencyCode | CNY |
|---|---|
| ISIN | CNE1000036K3 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | SHG |
| Market Cap | 5B |
|---|---|
| PE Ratio | 103.18 |
| Target Price | 44.55 |
| Beta | 0.72 |
| Dividend Yield | None |
Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. The company offers agkistrodon acutus hemocoagulase under Suling trade name, a single-component hemocoagulase clinical hemostatic drug for surgical operations. It is also involved in the development of drug candidates, including CX1026 for the treatment of lung, liver, kidney, colon, and skin T lymphocyte cancer; CX1003, which is in phase 1 trial for the treatment of solid tumors/preferably rare tumors; ZY5301 that is in phase 3 clinical trials for the treatment of chronic pelvic pain in sequelae of pelvic inflammatory disease; KC-B173 for bleeding and prevention of bleeding during surgical or invasive procedures; and KC1036, which is in phase 2 clinical trial for the treatment of solid tumors. The company was founded in 2003 and is headquartered in Beijing, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 603590.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
